v3.26.1
Leases (Additional Information) (Details)
$ in Thousands
 6 Months Ended 12 Months Ended
Feb. 15, 2018
ft²
Jun. 30, 2026
USD ($)
ft²
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2021
USD ($)
ft²
Lessee, Lease, Description [Line Items]            
Lease Premises Terminated | ft²   12,750        
Accelerated amortization expense on right-of-use asset   $ 1,000        
Non-cash impairment of the right-of-use asset   4,100        
Loss on impairment of lease right-of-use asset   0 $ 4,130      
Operating lease assets   6,688   $ 7,064    
Operating lease, liability   $ 9,879        
Freezers            
Lessee, Lease, Description [Line Items]            
Operating lease assets         $ 50,800  
Operating lease, liability         $ 4,800  
Research and Development Expense [Member]            
Lessee, Lease, Description [Line Items]            
Gain on derecognition of operating lease liability     700      
Gain on Derecognition of the Finance Lease Liability     $ 500      
South San Francisco California | Line of credit            
Lessee, Lease, Description [Line Items]            
Restricted Cash and Cash Equivalent, Noncurrent           $ 100
Letter of credit issued, classified as long-term restricted cash           $ 100
Thousand Oaks California            
Lessee, Lease, Description [Line Items]            
Lease initial term 15 years         10 years 6 months
Percentage of annual increase in base rent           3.00%
Lease commencement date Feb. 15, 2018          
Lease agreement area of office lab and cellular therapy manufacturing space | ft² 90,580         33,659
Operating lease assets       3,400    
Operating lease, liability       6,000    
Thousand Oaks California | Research and Development Arrangement [Member]            
Lessee, Lease, Description [Line Items]            
Gain (Loss) on Investments, Total       $ 2,600